Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Seres Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Seres Therapeutics, Inc.’s stock price such as:

• Seres Therapeutics, Inc.’s current stock price and volume
• Why Seres Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for MCRB from analysts
• MCRB’s stock price momentum as measured by its relative strength

About Seres Therapeutics, Inc. (MCRB)

Before we jump into Seres Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Seres Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Seres Therapeutics, Inc..

Seres Therapeutics, Inc.’s Stock Price as of Market Close

As of March 04, 2025, 4:00 PM, CST, Seres Therapeutics, Inc.’s stock price was $0.670.

Seres Therapeutics, Inc. is down 10.5% from its previous closing price of $0.749.

During the last market session, Seres Therapeutics, Inc.’s stock traded between $0.630 and $0.730. Currently, there are approximately 152.65 million shares outstanding for Seres Therapeutics, Inc..

Seres Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Seres Therapeutics, Inc. Stock Price History

Seres Therapeutics, Inc.’s (MCRB) price is currently down 11.75% so far this month.

During the month of March, Seres Therapeutics, Inc.’s stock price has reached a high of $0.780 and a low of $0.630.

Over the last year, Seres Therapeutics, Inc. has hit prices as high as $1.530 and as low as $0.540. Year to date, Seres Therapeutics, Inc.’s stock is down 19.36%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Seres Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of March 03, 2025,, no analysts have changed their rating of Seres Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Seres Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Seres Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Seres Therapeutics, Inc. (MCRB) by visiting AAII Stock Evaluator.

Relative Price Strength of Seres Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 03, 2025, Seres Therapeutics, Inc. has a weighted four-quarter relative price strength of -13.00%, which translates to a Momentum Score of 22 and is considered to be Weak.

Want to learn more about how Seres Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Seres Therapeutics, Inc. Stock Price: Bottom Line

As of March 4, 2025, Seres Therapeutics, Inc.’s stock price is $0.670, which is down 10.5% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Seres Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.